Entresto's Theoretical Alzheimer's Risk Draws Practical FDA Response
Executive Summary
FDA's authority to require post-marketing studies can extend to theoretical risks, even in absence of clinical evidence, office director Unger concluded when he overrode review team's more informal consensus with Novartis about how to address hypothetical risk of Alzheimer's from the heart failure drug; see our November Drug Review Profile.